Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B

NCT ID: NCT02881008

Last Updated: 2018-09-19

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 48 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2012-11-14
• Study Completion Date: 2014-10-04

Brief Summary

A randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B.

Detailed Description

This is a randomized, open-label multicentre clinical trial of daily Myrcludex B versus entecavir in patients with HBeAg negative chronic hepatitis B. Accounting for screen-outs about 76 patients will be screened and 48 of them will be randomized into 6 treatment groups:

Arm A (8 patients): Myrcludex B 0.5 mg / day / sc / 12 weeks Arm B (8 patients): Myrcludex B 1 mg / day / sc / 12 weeks Arm C (8 patients): Myrcludex B 2 mg / day / sc / 12 weeks Arm D (8 patients): Entecavir 0.5 mg / day / orally / 24 weeks Arm E (8 patients): Myrcludex B 5 mg / day / sc / 12 weeks Arm F (8 patients): Myrcludex B 10 mg / day / sc / 24 weeks

The study consists of screening period up to 28 days (Day -28 -1); baseline visit (Day 0), treatment period up to 12 weeks for groups A-C, E and 24 weeks for groups D, F; follow-up period up to 12 weeks for groups A-C, E, F.

Conditions

Chronic Hepatitis B

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Arm A

Myrcludex B 0.5 mg daily for 12 weeks, followed by 12 weeks follow-up period

Group Type: EXPERIMENTAL

Myrcludex B

Intervention Type: DRUG

Arm B

Myrcludex B 1 mg daily for 12 weeks, followed by 12 weeks follow-up period

Group Type: EXPERIMENTAL

Myrcludex B

Intervention Type: DRUG

Arm C

Myrcludex B 2 mg daily for 12 weeks, followed by 12 weeks follow-up period

Group Type: EXPERIMENTAL

Myrcludex B

Intervention Type: DRUG

Arm D

Entecavir 0.5 mg daily for 24 weeks

Group Type: ACTIVE_COMPARATOR

Entecavir

Intervention Type: DRUG

Arm E

Myrcludex B 5 mg daily for 12 weeks, followed by 12 weeks follow-up period

Group Type: EXPERIMENTAL

Myrcludex B

Intervention Type: DRUG

Arm F

Myrcludex B 10 mg daily for 24 weeks, followed by 12 weeks follow-up period

Group Type: EXPERIMENTAL

Myrcludex B

Intervention Type: DRUG

Interventions

Entecavir

Intervention Type: DRUG

Myrcludex B

Intervention Type: DRUG

Other Intervention Names

Baraclude®; Myrcludex

Eligibility Criteria

Inclusion Criteria

1. Age 18-65 years inclusive at the time of giving of written informed consent for study participation.

2. Chronic hepatitis B defined by the presence of HBsAg for at least 6 months prior to screening period.

3. Liver biopsy performed within one year prior to screening or during screening period.

4. Alanine aminotransferase (ALT) ≥1.5 x ULN and ≤ 6 x ULN. If ALT level during screening period is ≥1 ULN the patient can be included in the study after obtaining the sponsor's approval and if the following conditions are met :

• evidence of inflammation such as lymphocyte infiltration confirmed by liver biopsy performed within the 6 months prior to the inclusion in the study,
• and/or the patient has a history of elevated ALT levels of ≥1.5 ULN during the 12 months prior to screening period.

5. HBeAg negative and anti-HBeAg positive.

6. HBV DNA ≥ 104 copies/mL.

7. All women of childbearing potential must have a negative urine pregnancy test prior to enrolment.

8. Women must:

• Be menopausal for at least 2 years, or
• Be surgically sterile (total hysterectomy or bilateral ovariectomy or bilateral tubal ligation/clips or otherwise be incapable of pregnancy), or
• Not be heterosexually active during the study, or
• Agree to use a highly effective method of birth control (double barrier method or combination of barrier method with hormonal or intrauterine device) during the study and for 3 month after the last dosing of the investigational medicinal product.

9. Men must agree to use a highly effective method of birth control (double barrier methods or combination of barrier method with hormonal or intrauterine device in their women-partner) and not to donate a sperm during the study and for 3 month after the last dosing of the investigational medicinal product.

10. An understanding, ability and willingness to fully comply with study procedures and restrictions.

11. An ability to provide the written informed consent to participate in the study.

Exclusion Criteria

1. Decompensated liver disease (Child-Pugh-Score >6).

2. Any sign of liver cirrhosis (histological, ultra sound, biochemical).

3. Co-infected with hepatitis C virus (HCV), hepatitis D virus (HDV), or HIV.

4. ALT > 6 ULN.

5. Creatinine clearance < 60 mL/min.

6. Total bilirubin > 2 mg/dL.

7. Pre-treatment with nucleoside-analogues (lamivudine, telbivudine, entecavir) less than 6 months prior to the first dosing of the investigational medicinal products. Pre-treatment with nucleotide-analogues and interferons is allowed.

8. History of hepatocellular carcinoma (HCC) or findings suggestive of possible HCC, such as suspicious foci on imaging studies or elevated serum alpha-fetoprotein (AFP) levels. In patients with such findings, HCC will be ruled-out prior to screening for the present study.

9. One or more additional known primary or secondary causes of liver disease, other than hepatitis B (e.g., alcoholism, autoimmune hepatitis, malignancy with hepatic involvement, hemochromatosis, alpha-1 antitrypsin deficiency, Wilson's Disease, other congenital or metabolic conditions affecting the liver, e.g. congestive heart failure or other severe cardiopulmonary disease). Patients with Gilbert's syndrome and Dubin-Johnson syndrome, two benign disorders associated with low-grade hyperbilirubinemia can be enrolled into the trial.

10. History of clinically evident pancreatitis.

11. History of alcohol or drug abuse within the preceding two years. For the purposes of the present study, alcohol abuse is arbitrarily defined as frequent consumption of alcoholic beverages with an average daily intake of more than 40 g of ethanol.

12. Participation in another study with an investigational drug within less than one month prior to this study or simultaneously to this study.

13. Patients who are unable or unwilling to follow the protocol requirements.

14. Patients with a history of seizures, central nervous system disorders or psychiatric disability thought to be clinically significant in the opinion of the investigator.

15. Patients with limited mental capacity to the extent that she/he cannot provide informed consent or information regarding adverse events of the study drug.

16. Clinically significant renal, respiratory or cardiovascular disease.

17. Pregnancy and lactation.

18. Patients who have previously participated in this study.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Hepatera Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Pavel Bogomolov, PhD

Role: PRINCIPAL_INVESTIGATOR

LLC "Clinical Hospital of Tsentrosoyuz"

Locations

SBEI of Higher Professional Education "South Ural State Medical university" of the MoH of the RF

Chelyabinsk, , Russia

1-st MMU n.a. I.M. Sechenov based in Moscow State-Owned Health Care Institution "Infectious Clinical Hospital № 2 of Moscow Healthcare Department"

Moscow, , Russia

FSBI of Higher Education "People's Friendship University"

Moscow, , Russia

FSBHI "Central Clinical Hospital RAS"

Moscow, , Russia

LLC "Clinical Hospital of Tsentrosoyuz"

Moscow, , Russia

SPb SBHI "The Center for Prevention and Control of AIDS and Infectious Diseases"

Saint Petersburg, , Russia

SPb SIH "Clinical Centre of Infectious Diseases Named After S.P. Botkin"

Saint Petersburg, , Russia

Medical Company "Hepatolog" LLC

Samara, , Russia

SBIH "Stavropol Regional Clinical Hospital"

Stavropol, , Russia

Countries

Russia

References

Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004 Mar;11(2):97-107. doi: 10.1046/j.1365-2893.2003.00487.x.

Reference Type: BACKGROUND

PMID: 14996343 (View on PubMed)

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;1:e00049. doi: 10.7554/eLife.00049.

Reference Type: BACKGROUND

PMID: 23150796 (View on PubMed)

Trauner M, Boyer JL. Bile salt transporters: molecular characterization, function, and regulation. Physiol Rev. 2003 Apr;83(2):633-71. doi: 10.1152/physrev.00027.2002.

Reference Type: BACKGROUND

PMID: 12663868 (View on PubMed)

Lok AS, McMahon BJ. Chronic hepatitis B: update 2009. Hepatology. 2009 Sep;50(3):661-2. doi: 10.1002/hep.23190. No abstract available.

Reference Type: BACKGROUND

PMID: 19714720 (View on PubMed)

Nowak MA, Bonhoeffer S, Hill AM, Boehme R, Thomas HC, McDade H. Viral dynamics in hepatitis B virus infection. Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4398-402. doi: 10.1073/pnas.93.9.4398.

Reference Type: BACKGROUND

PMID: 8633078 (View on PubMed)

Yan H, Zhong G, Xu G, He W, Jing Z, Gao Z, Huang Y, Qi Y, Peng B, Wang H, Fu L, Song M, Chen P, Gao W, Ren B, Sun Y, Cai T, Feng X, Sui J, Li W. Sodium taurocholate cotransporting polypeptide is a functional receptor for human hepatitis B and D virus. Elife. 2012 Nov 13;3. doi: 10.7554/eLife.00049.

Reference Type: BACKGROUND

PMID: 25409679 (View on PubMed)

Other Identifiers

MYR 201 (HBV)

Identifier Type: -

Identifier Source: org_study_id